- Home
- SGU vs FBRX Comparison
SGU vs FBRX Comparison
Compare SGU & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGU | FBRX |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.0M | 487.2M |
| IPO Year | 1997 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SGU | FBRX |
|---|---|---|
| Price | $12.86 | $24.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $67.00 |
| AVG Volume (30 Days) | 22.3K | ★ 204.0K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.90% | N/A |
| EPS Growth | N/A | ★ 61.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,784,418,000.00 | $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.70 | ★ N/A |
| Revenue Growth | ★ 1.04 | N/A |
| 52 Week Low | $11.31 | $7.00 |
| 52 Week High | $13.53 | $35.80 |
Technical Indicators
Market Signals| Indicator | SGU | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.63 | 41.38 |
| Support Level | $12.31 | $22.33 |
| Resistance Level | $12.99 | $30.43 |
| Average True Range (ATR) | 0.34 | 2.12 |
| MACD | 0.01 | -0.47 |
| Stochastic Oscillator | 39.84 | 19.11 |
Price Performance
Historical ComparisonAbout SGU Star Group L.P.
Star Group LP is a home heating oil and propane distributor and services provider with one reportable operating segment that principally provides heating related services to residential and commercial customers. It serves residential and commercial customers whose primary use is to heat their homes and buildings in the Northeast and Mid-Atlantic U.S. regions. The company derives the majority of revenue from Petroleum products, which consist of home heating oil and propane as well as diesel fuel and gasoline.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.